
Amgen is pinning its hopes on investigational viral treatment T-VEC following promising results from a ‘landmark’ skin cancer study. People …

Amgen has ended its agreement with AstraZeneca to develop a new biologic for psoriasis, because of the likelihood of ‘restrictive …

The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …

Amgen has appointed Jonathan Graham as its senior vice president, general counsel and secretary who will take to his post in July. …
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …

Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …

Amgen has earned sign-off from the FDA for Corlanor as a treatment for people with worsening heart failure symptoms. Corlanor …

Pfizer is funding a new competitive grants programme to support research projects in the burgeoning, competitive area of cholesterol-lowering PCSK9 …

The European Commission has shown Amgen’s cancer drug Vectibix the green light to treat patients in combination with chemotherapy for …

Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …

Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …

Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …

The Association of the British Pharmaceutical Industry has appointed John Kearney as its new president. Stepping into the role in …

Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …

The Association of the British Pharmaceutical Industry (ABPI) has named Dr Virginia Acha as its new executive director of Research …